Conclusions
The results of this study provide pharmacokinetic and pharmacodynamic evidence to support the use of ravulizumab every 8 weeks for immediate (within 30 min of the end of the first infusion), complete, and sustained inhibition of terminal complement in patients with AChR Ab+ gMG.